PURPOSE: It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. We evaluated the effect of concomitant clinical carcinoma in situ on cancer specific outcomes after neoadjuvant chemotherapy for muscle invasive bladder cancer. MATERIALS AND METHODS: We performed an institutional review board approved, multi-institutional, retrospective review of the records of patients treated with neoadjuvant chemotherapy followed by radical cystectomy for muscle invasive bladder cancer from 2008 to 2012. Pretreatment clinical variables were collected and patients were stratified by the presence of clinical carcinoma in situ on precystectomy transurethral bladder tumor resection specimens. Pathological outcomes, including the complete response rate (pT0N0Mx) after neoadjuvant chemotherapy, were compared between the 2 groups. Recurrence-free, cancer specific and overall survival was analyzed. RESULTS: Of 189 patients who met study criteria 56 (29.6%) had concomitant carcinoma in situ. The condition was associated with a significant decrease in the pathological complete response rate (10.7% vs 26.3%, p = 0.02). This difference was significant on univariate and multivariable analysis (OR 0.34, 95% CI 0.13-0.85, p = 0.02 and OR 0.31, 95% CI 0.12-0.81, p = 0.02, respectively). Despite the decreased complete response rate clinical carcinoma in situ was not associated with a difference in recurrence-free, cancer specific or overall survival. Additionally, when down-staging to pathological carcinoma in situ only disease was considered a complete response, there was no significant change in recurrence-free, cancer specific or overall survival. CONCLUSIONS: Concomitant carcinoma in situ is associated with a decrease in the complete response rate but this does not appear to impact the survival outcome.
PURPOSE: It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. We evaluated the effect of concomitant clinical carcinoma in situ on cancer specific outcomes after neoadjuvant chemotherapy for muscle invasive bladder cancer. MATERIALS AND METHODS: We performed an institutional review board approved, multi-institutional, retrospective review of the records of patients treated with neoadjuvant chemotherapy followed by radical cystectomy for muscle invasive bladder cancer from 2008 to 2012. Pretreatment clinical variables were collected and patients were stratified by the presence of clinical carcinoma in situ on precystectomy transurethral bladder tumor resection specimens. Pathological outcomes, including the complete response rate (pT0N0Mx) after neoadjuvant chemotherapy, were compared between the 2 groups. Recurrence-free, cancer specific and overall survival was analyzed. RESULTS: Of 189 patients who met study criteria 56 (29.6%) had concomitant carcinoma in situ. The condition was associated with a significant decrease in the pathological complete response rate (10.7% vs 26.3%, p = 0.02). This difference was significant on univariate and multivariable analysis (OR 0.34, 95% CI 0.13-0.85, p = 0.02 and OR 0.31, 95% CI 0.12-0.81, p = 0.02, respectively). Despite the decreased complete response rate clinical carcinoma in situ was not associated with a difference in recurrence-free, cancer specific or overall survival. Additionally, when down-staging to pathological carcinoma in situ only disease was considered a complete response, there was no significant change in recurrence-free, cancer specific or overall survival. CONCLUSIONS: Concomitant carcinoma in situ is associated with a decrease in the complete response rate but this does not appear to impact the survival outcome.
Authors: N Vasdev; H Zargar; J P Noël; R Veeratterapillay; A S Fairey; L S Mertens; C P Dinney; M C Mir; L M Krabbe; M S Cookson; N E Jacobsen; N M Gandhi; J Griffin; J S Montgomery; E Y Yu; E Xylinas; N J Campain; W Kassouf; M A Dall'Era; J A Seah; C E Ercole; S Horenblas; S S Sridhar; J S McGrath; J Aning; S F Shariat; J L Wright; T M Morgan; T J Bivalacqua; S North; D A Barocas; Y Lotan; P Grivas; A J Stephenson; J B Shah; B W van Rhijn; S Daneshmand; P E Spiess; J M Holzbeierlein; A Thorpe; P C Black Journal: World J Urol Date: 2018-06-07 Impact factor: 4.226
Authors: Derek E Thomas; Hristos Z Kaimakliotis; Kevin R Rice; Jose A Pereira; Paul Johnston; Marietta L Moore; Angela Reed; Dylan M Cregar; Cindy Franklin; Rhoda L Loman; Michael O Koch; Richard Bihrle; Richard S Foster; Timothy A Masterson; Thomas A Gardner; Chandru P Sundaram; Charles R Powell; Stephen D W Beck; David J Grignon; Liang Cheng; Costantine Albany; Noah M Hahn Journal: Clin Genitourin Cancer Date: 2016-11-30 Impact factor: 2.872
Authors: Erfan Amini; Nariman Ahmadi; Thomas G Clifford; Cory M Hugen; Soroush T Bazargani; Jie Cai; Gus Miranda; Andy E Sherrod; Siamak Daneshmand; Hooman Djaladat Journal: Int Urol Nephrol Date: 2019-01-31 Impact factor: 2.370